Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

62-21-648-WC WCLC 1200x600

Activity Overview

This activity has been designed to meet the educational needs of healthcare providers involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

1.00 CE Credit(s)
Expires: September 9, 2021

Target Audience

This activity is intended for medical oncology, pathology, and pulmonology clinicians attending the virtual IASLC 2021 World Conference on Lung Cancer meeting and who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Analyze the predictive/prognostic significance of EGFR exon 20 insertion
    mutations in non-small cell lung cancer (NSCLC)
  •  Apply optimal diagnostic strategies for identifying NSCLC with EGFR
    exon 20 insertions
  • Assess clinical trial data regarding new and emerging treatment options
    for advanced NSCLC with EGFR exon 20 insertions
  • Employ appropriate techniques to manage adverse events associated
    with EGFR inhibition

Activity Faculty


Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO (Chair)

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China


Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI


Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy